Status:
COMPLETED
GIP: Glucose-dependent Insulinotropic Peptide
Lead Sponsor:
National Institute on Aging (NIA)
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the safety of glucose-dependent insulinotropic peptide (GIP)/GIP Analog on people with Type 2 Diabetes.
Detailed Description
The small bowel makes a hormone called glucose-dependent insulinotropic peptide (GIP). It is released into the blood stream and goes to the pancreas. It works there with nutrients, especially glucose,...
Eligibility Criteria
Inclusion
- 18 years of age and older
- Healthy Type 2 Diabetics
- Agree to stay off glucosidases for 3 days prior to infusion visits (Examples: Precose, Glyset)
- Agree to stay off Sulfonylureas 5 days prior to infusion visits (Examples: Glucotrol, Amaryl, glyburide, metformin
- Able to ingest 1000 mg Tylenol on study visits
- Able to consume study breakfast consisting of scrambled egg, white toast with margarine, corn flakes, 2% milk, banana at each infusion visit
- Female participants must have Hct \> 36
- Male participant must have Hct \> 38
- No kidney or liver disease per history and evidenced by blood and urine tests
- Physical Exam and EKG that do not contraindicate patient to be in the study
Exclusion
- Taking the following medications: Insulin, or Thiazolidinediones, i.e. Avandia, Actos
- Pregnancy
- Steroid use within the past 3 months
- Recent infection, fever or chills
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00239707
Start Date
February 1 2003
End Date
December 1 2006
Last Update
November 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute on Aging, Clinical Research Branch
Baltimore, Maryland, United States, 21225